Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 study assessing safety, tolerability, pharmacokinetics and pharmacodynamics of DNTH103 in healthy adult volunteers across single and multiple ascending dose cohorts

Next Previous
Trial Profile

Phase 1 study assessing safety, tolerability, pharmacokinetics and pharmacodynamics of DNTH103 in healthy adult volunteers across single and multiple ascending dose cohorts

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DNTH 103 (Primary)
  • Indications Autoimmune disorders
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Dianthus Therapeutics

Most Recent Events

  • 09 May 2024 According to a Dianthus Therapeutics media release, R&D expenses for the this quarter ended were $13.1 million, including $0.8 million of stock-based compensation, compared to $5.8 million for March 31, 2023, including $0.2 million of stock-based compensation. This increase in expenses was primarily driven by higher clinical, CMC costs and increased headcount to support DNTH103 Phase 1 and Phase 2 development, partially offset by lower pre-clinical costs.
  • 12 Sep 2023 Top-line results presented in a Dianthus Therapeutics media release.
  • 03 May 2023 According to a Dianthus Therapeutics media release, data from this trial is expected by the end of 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top